Drug Profile
Alagebrium chloride
Alternative Names: Alagebrium; ALT-711Latest Information Update: 23 Sep 2021
Price :
$50
*
At a glance
- Originator Alteon
- Developer Synvista Therapeutics
- Class Cardiovascular therapies; Small molecules; Thiazoles
- Mechanism of Action Advanced glycosylation end product inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetic nephropathies; Diastolic heart failure; Erectile dysfunction; Heart failure; Hypertension
Most Recent Events
- 28 Jan 2009 Discontinued - Phase-II for Diastolic heart failure in USA (PO)
- 28 Jan 2009 Discontinued - Phase-II for Heart failure in Netherlands (PO)
- 28 Jan 2009 Discontinued - Preclinical for Diabetic nephropathies in USA (PO)